论文部分内容阅读
目的:探讨肝胆管癌组织中骨桥蛋白的表达及其与抗药性的关系。方法:⑴采用实时定量PCR检测胆管癌及正常胆管组织骨桥蛋白mRNA的表达,并分析其表达与临床病理特征的关系;⑵应用靶向RNA干扰骨桥蛋白基因的技术构建骨桥蛋白低表达的细胞模型,并以CCK-8法检测5-FU对RBE胆管癌细胞增殖的抑制作用。结果:⑴胆管癌中骨桥蛋白的阳性表达率明显高于正常胆管组织(P<0.01),骨桥蛋白mRNA表达水平与胆管癌的分化程度、肿瘤分期和淋巴结转移有关,上述指标的分组差异有统计学意义(P<0.01),而与年龄、性别、肿瘤类型和病理类型等无明显关系,各组间比较差异无统计学意义(P>0.05)。⑵经沉默骨桥蛋白基因的RBE胆管癌细胞的骨桥蛋白mRNA表达显著降低(P<0.01);且5-FU和顺铂抑制肿瘤细胞生长的IC50均显著降低(P<0.01)。结论:骨桥蛋白在胆管癌的发生、发展及产生抗药性方面起着一定的作用。
Objective: To investigate the expression of osteopontin in hepatocellular carcinoma and its relationship with drug resistance. Methods: (1) The expression of osteopontin mRNA in cholangiocarcinoma and normal bile duct tissues was detected by real-time quantitative PCR, and its relationship with clinicopathological features was analyzed. (2) The expression of osteopontin Cell model, and CCK-8 assay 5-FU on RBE cholangiocarcinoma cell proliferation inhibition. Results: (1) The positive expression of osteopontin in cholangiocarcinoma was significantly higher than that in normal bile duct tissue (P <0.01). The osteopontin mRNA expression was related to the differentiation of cholangiocarcinoma, tumor stage and lymph node metastasis. (P <0.01), but not with the age, sex, tumor type and pathological type. There was no significant difference among the groups (P> 0.05). (2) Osteopontin mRNA expression in RBE cholangiocarcinoma cells with silencing of osteopontin gene was significantly decreased (P <0.01); and the IC50 of 5-FU and cisplatin inhibiting tumor cell growth were significantly decreased (P <0.01). Conclusion: Osteopontin play a role in the occurrence, development and drug resistance of cholangiocarcinoma.